Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes

Tools
- Tools
+ Tools

Waugh, Norman, Cummins, E. (Ewen), Shyangdan, D. (Deepson), Court, Rachel A. and Mohiuddin, Syed (2012) Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes. Manchester: National Institute for Health and Clinical Excellence (NICE). (NICE technology appraisal guidance).

[img]
Preview
Text
WRAP_Waugh_Exenatide_prolonged_release.pdf - Published Version

Download (287Kb) | Preview
Official URL: http://www.nice.org.uk/ta248

Request Changes to record.

Abstract

Prolonged-release exenatide in triple therapy regimens (that is, in combination
with metformin and a sulphonylurea, or metformin and a thiazolidinedione) is
recommended as a treatment option for people with type 2 diabetes as
described in 'Type 2 diabetes: the management of type 2 diabetes (NICE
clinical guideline 87); that is, when control of blood glucose remains or
becomes inadequate (HbA1c ≥ 7.5% [59 mmol/mol] or other higher level agreed
with the individual), and the person has:
a body mass index (BMI) ≥ 35 kg/m2 in those of European family origin (with
appropriate adjustment for other ethnic groups) and specific psychological or
medical problems associated with high body weight or
a BMI < 35 kg/m2, and therapy with insulin would have significant occupational
implications or weight loss would benefit other significant obesity-related
comorbidities.

Item Type: Report
Subjects: R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET) > Warwick Evidence
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Non-insulin-dependent diabetes -- Treatment
Series Name: NICE technology appraisal guidance
Publisher: National Institute for Health and Clinical Excellence (NICE)
Place of Publication: Manchester
Official Date: February 2012
Dates:
DateEvent
February 2012Published
Volume: No.248
Number of Pages: 55
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Date of first compliant deposit: 1 August 2016
Date of first compliant Open Access: 1 August 2016

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us